<ul>
<li>关注这只生物科技股票，它仍然具有巨大的潜在上涨空间</li>
</ul>
<p>Centessa Pharmaceuticals PLC 赞助的 ADR (NASDAQ:CNTA - 免费报告) - Lifesci Capital 的分析师在 11 月 13 日星期四发布的研究报告中上调了对 Centessa Pharmaceuticals 2025 财年的盈利预期。Lifesci Capital 分析师 F. Brisebois 现在预计该公司将发布每股收益为（$1.37），高于之前的预期（$1.39）。Lifesci Capital 目前对该股票的评级为 “强力买入”。市场普遍预计 Centessa Pharmaceuticals 当前全年的每股收益为（$1.60）。Lifesci Capital 还对 Centessa Pharmaceuticals 2025 年第四季度的每股收益预期为（$0.39），2026 年第一季度的每股收益预期为（$0.39），2026 年第二季度的每股收益预期为（$0.39），2026 年第三季度的每股收益预期为（$0.42），2026 年第四季度的每股收益预期为（$0.42），以及 2026 财年的每股收益预期为（$1.61）。</p>
<p>其他一些股票分析师也对 CNTA 发表了看法。华尔街 Zen 在 10 月 27 日星期一的研究报告中将 Centessa Pharmaceuticals 的评级从 “卖出” 上调至 “持有”。Stephens 在 10 月 28 日星期二的报告中开始覆盖 Centessa Pharmaceuticals。他们对该股票设定了 “超配” 评级和 $35.00 的目标价。Chardan Capital 在 8 月 12 日星期二的报告中重申了 “买入” 评级，并对 Centessa Pharmaceuticals 的股票设定了 $30.00 的目标价。Weiss Ratings 在 10 月 8 日星期三的研究报告中重申了 Centessa Pharmaceuticals 股票的 “卖出（d-）” 评级。最后，Truist Financial 在 11 月 5 日星期三的报告中对 Centessa Pharmaceuticals 股票设定了 $30.00 的目标价。一位股票研究分析师对该股票给予了强力买入评级，十位分析师给予了买入评级，一位分析师给予了卖出评级。根据 MarketBeat 的数据，该公司的平均评级为 “适度买入”，共识目标价为 $33.11。</p>
<p><strong>查看我们对 CNTA 的最新分析</strong></p>
<h2>Centessa Pharmaceuticals 价格表现</h2>
<p>CNTA 股票在星期一开盘价为 $27.61。Centessa Pharmaceuticals 的一年最低价为 $9.60，一年最高价为 $27.72。该公司的债务与股本比率为 0.36，流动比率为 10.56，速动比率为 10.57。该公司的市值为 37 亿美元，市盈率为 -15.09，贝塔值为 1.56。该公司的 50 日简单移动平均为 $23.17，200 日简单移动平均为 $17.56。</p>
<p>Centessa Pharmaceuticals (NASDAQ:CNTA - 获取免费报告) 最近在 11 月 5 日星期三发布了季度财报。该公司报告的每股收益为（$0.41），低于分析师的共识预期（$0.39）$0.02。</p>
<h2>Centessa Pharmaceuticals 内部活动</h2>
<p>在相关消息中，内部人士 Mario Alberto Accardi 在 10 月 27 日星期一以每股平均价格 $25.00 出售了 8,000 股该公司的股票，总价值为 $200,000.00。出售后，该内部人士在公司中持有 194,394 股，价值约为 $4,859,850。这笔交易使其持股减少了 3.95%。该交易已在证券交易委员会的备案中披露，可以通过此链接访问。此外，首席技术官 Tia L. Bush 在 11 月 12 日星期三以每股平均价格 $26.00 出售了 40,000 股该公司的股票，总价值为 $1,040,000.00。交易后，首席技术官持有 121,503 股公司股票，价值 $3,159,078。这笔交易代表其持股减少了 24.77%。该销售的 SEC 备案提供了更多信息。在上个季度，内部人士出售了价值 $4,106,481 的 179,964 股公司股票。内部人士持有公司股票的比例为 7.09%。</p>
<h2>Centessa Pharmaceuticals 的机构交易</h2>
<p>几家对冲基金最近对 CNTA 的持仓进行了调整。Avoro Capital Advisors LLC 在第三季度将其在 Centessa Pharmaceuticals 的股份增加了 116.2%。Avoro Capital Advisors LLC 现在拥有 10,808,080 股该公司的股票，价值 $262,096,000，此前在此期间又购买了 5,808,080 股。Adage Capital Partners GP L.L.C. 在第一季度将其在 Centessa Pharmaceuticals 的持股增加了 35.8%。Adage Capital Partners GP L.L.C. 现在拥有 6,954,000 股该公司的股票，价值 $99,999,000，此前在上个季度又购买了 1,834,973 股。Federated Hermes Inc. 在第三季度购买了 Centessa Pharmaceuticals 的新头寸，价值约为 $42,429,000。Balyasny Asset Management L.P. 在第二季度获得了 Centessa Pharmaceuticals 的新头寸，价值 $16,052,000。最后，Commodore Capital LP 在第二季度将其在 Centessa Pharmaceuticals 的持仓增加了 39.3%。Commodore Capital LP 现在拥有 3,298,289 股该公司的股票，价值 $43,340,000，此前在此期间又购买了 930,711 股。机构投资者和对冲基金持有公司股票的比例为 82.01%。</p>
<h2>Centessa Pharmaceuticals 公司简介</h2>
<p>（获取免费报告）</p>
<p>Centessa Pharmaceuticals plc 是一家临床阶段的制药公司，致力于为患者发现、开发和提供药物。其产品管线包括 SerpinPC，一种用于治疗 A 型和 B 型血友病的活化蛋白 C 抑制剂；以及 ORX750，一种用于治疗嗜睡症和其他睡眠障碍的口服 OX2R 激动剂。</p>
<h2>另请参阅</h2>
<ul>
<li>我们更看好的五只股票，胜过 Centessa Pharmaceuticals</li>
<li>内部人士出售解释：它能否影响你的投资选择？</li>
<li>4 只寒冷天气股票，适合冬季消费热潮</li>
<li>深入了解买卖差价</li>
<li>迪士尼股票下跌——收益能否为 YouTube TV 和解铺平道路？</li>
<li>股息筛选器：如何在购买前评估股息股票</li>
<li>Meta 的痛苦可能是你的机会：这是一个罕见的买入窗口吗？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q05UQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q05UQQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Centessa Pharmaceuticals 吗？</h2>
<p>在你考虑 Centessa Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Centessa Pharmaceuticals 并不在名单上。</p>
<p>虽然 Centessa Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

CNTA

<p>Lifesci Capital 已上调 Centessa Pharmaceuticals 的 2025 财年盈利预期，现在预计每股收益为（$1.37），高于之前的（$1.39）。该公司对该股票维持 “强力买入” 评级。Centessa 的股票共识目标价为 $33.11，平均评级为 “适度买入”。近期的内部交易和机构投资表明市场对该公司的显著兴趣。该股票开盘价为 $27.61，市值为 37 亿美元</p>

<ul>
<li>Wake Up to This Biotech Stock That Still Has Big Potential Upside</li>
</ul>
<div class="lb-trans"><ul>
<li>关注这只生物科技股票，它仍然具有巨大的潜在上涨空间</li>
</ul>
</div><p>Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Free Report) - Analysts at Lifesci Capital raised their FY2025 earnings estimates for Centessa Pharmaceuticals in a research report issued on Thursday, November 13th. Lifesci Capital analyst F. Brisebois now anticipates that the company will post earnings per share of ($1.37) for the year, up from their previous estimate of ($1.39). Lifesci Capital currently has a &#34;Strong-Buy&#34; rating on the stock. The consensus estimate for Centessa Pharmaceuticals' current full-year earnings is ($1.60) per share. Lifesci Capital also issued estimates for Centessa Pharmaceuticals' Q4 2025 earnings at ($0.39) EPS, Q1 2026 earnings at ($0.39) EPS, Q2 2026 earnings at ($0.39) EPS, Q3 2026 earnings at ($0.42) EPS, Q4 2026 earnings at ($0.42) EPS and FY2026 earnings at ($1.61) EPS.</p>
<div class="lb-trans"><p>Centessa Pharmaceuticals PLC 赞助的 ADR (NASDAQ:CNTA - 免费报告) - Lifesci Capital 的分析师在 11 月 13 日星期四发布的研究报告中上调了对 Centessa Pharmaceuticals 2025 财年的盈利预期。Lifesci Capital 分析师 F. Brisebois 现在预计该公司将发布每股收益为（$1.37），高于之前的预期（$1.39）。Lifesci Capital 目前对该股票的评级为 “强力买入”。市场普遍预计 Centessa Pharmaceuticals 当前全年的每股收益为（$1.60）。Lifesci Capital 还对 Centessa Pharmaceuticals 2025 年第四季度的每股收益预期为（$0.39），2026 年第一季度的每股收益预期为（$0.39），2026 年第二季度的每股收益预期为（$0.39），2026 年第三季度的每股收益预期为（$0.42），2026 年第四季度的每股收益预期为（$0.42），以及 2026 财年的每股收益预期为（$1.61）。</p>
</div><p>A number of other equities analysts have also weighed in on CNTA. Wall Street Zen raised Centessa Pharmaceuticals from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research note on Monday, October 27th. Stephens initiated coverage on Centessa Pharmaceuticals in a report on Tuesday, October 28th. They set an &#34;overweight&#34; rating and a $35.00 price target on the stock. Chardan Capital reissued a &#34;buy&#34; rating and issued a $30.00 price objective on shares of Centessa Pharmaceuticals in a report on Tuesday, August 12th. Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of Centessa Pharmaceuticals in a research report on Wednesday, October 8th. Finally, Truist Financial set a $30.00 target price on shares of Centessa Pharmaceuticals in a report on Wednesday, November 5th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $33.11.</p>
<div class="lb-trans"><p>其他一些股票分析师也对 CNTA 发表了看法。华尔街 Zen 在 10 月 27 日星期一的研究报告中将 Centessa Pharmaceuticals 的评级从 “卖出” 上调至 “持有”。Stephens 在 10 月 28 日星期二的报告中开始覆盖 Centessa Pharmaceuticals。他们对该股票设定了 “超配” 评级和 $35.00 的目标价。Chardan Capital 在 8 月 12 日星期二的报告中重申了 “买入” 评级，并对 Centessa Pharmaceuticals 的股票设定了 $30.00 的目标价。Weiss Ratings 在 10 月 8 日星期三的研究报告中重申了 Centessa Pharmaceuticals 股票的 “卖出（d-）” 评级。最后，Truist Financial 在 11 月 5 日星期三的报告中对 Centessa Pharmaceuticals 股票设定了 $30.00 的目标价。一位股票研究分析师对该股票给予了强力买入评级，十位分析师给予了买入评级，一位分析师给予了卖出评级。根据 MarketBeat 的数据，该公司的平均评级为 “适度买入”，共识目标价为 $33.11。</p>
</div><p><strong>Check Out Our Latest Analysis on CNTA</strong></p>
<div class="lb-trans"><p><strong>查看我们对 CNTA 的最新分析</strong></p>
</div><h2>Centessa Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>Centessa Pharmaceuticals 价格表现</h2>
</div><p>CNTA stock opened at $27.61 on Monday. Centessa Pharmaceuticals has a 1 year low of $9.60 and a 1 year high of $27.72. The company has a debt-to-equity ratio of 0.36, a current ratio of 10.56 and a quick ratio of 10.57. The firm has a market capitalization of $3.70 billion, a PE ratio of -15.09 and a beta of 1.56. The business has a 50 day simple moving average of $23.17 and a 200-day simple moving average of $17.56.</p>
<div class="lb-trans"><p>CNTA 股票在星期一开盘价为 $27.61。Centessa Pharmaceuticals 的一年最低价为 $9.60，一年最高价为 $27.72。该公司的债务与股本比率为 0.36，流动比率为 10.56，速动比率为 10.57。该公司的市值为 37 亿美元，市盈率为 -15.09，贝塔值为 1.56。该公司的 50 日简单移动平均为 $23.17，200 日简单移动平均为 $17.56。</p>
</div><p>Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.41) EPS for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.02).</p>
<div class="lb-trans"><p>Centessa Pharmaceuticals (NASDAQ:CNTA - 获取免费报告) 最近在 11 月 5 日星期三发布了季度财报。该公司报告的每股收益为（$0.41），低于分析师的共识预期（$0.39）$0.02。</p>
</div><h2>Insider Activity at Centessa Pharmaceuticals</h2>
<div class="lb-trans"><h2>Centessa Pharmaceuticals 内部活动</h2>
</div><p>In related news, insider Mario Alberto Accardi sold 8,000 shares of the business's stock in a transaction on Monday, October 27th. The stock was sold at an average price of $25.00, for a total value of $200,000.00. Following the sale, the insider owned 194,394 shares in the company, valued at approximately $4,859,850. The trade was a 3.95% decrease in their position. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink. Also, CTO Tia L. Bush sold 40,000 shares of the firm's stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $26.00, for a total value of $1,040,000.00. Following the transaction, the chief technology officer owned 121,503 shares of the company's stock, valued at $3,159,078. This trade represents a 24.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 179,964 shares of company stock worth $4,106,481. Insiders own 7.09% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，内部人士 Mario Alberto Accardi 在 10 月 27 日星期一以每股平均价格 $25.00 出售了 8,000 股该公司的股票，总价值为 $200,000.00。出售后，该内部人士在公司中持有 194,394 股，价值约为 $4,859,850。这笔交易使其持股减少了 3.95%。该交易已在证券交易委员会的备案中披露，可以通过此链接访问。此外，首席技术官 Tia L. Bush 在 11 月 12 日星期三以每股平均价格 $26.00 出售了 40,000 股该公司的股票，总价值为 $1,040,000.00。交易后，首席技术官持有 121,503 股公司股票，价值 $3,159,078。这笔交易代表其持股减少了 24.77%。该销售的 SEC 备案提供了更多信息。在上个季度，内部人士出售了价值 $4,106,481 的 179,964 股公司股票。内部人士持有公司股票的比例为 7.09%。</p>
</div><h2>Institutional Trading of Centessa Pharmaceuticals</h2>
<div class="lb-trans"><h2>Centessa Pharmaceuticals 的机构交易</h2>
</div><p>Several hedge funds have recently made changes to their positions in CNTA. Avoro Capital Advisors LLC boosted its stake in shares of Centessa Pharmaceuticals by 116.2% in the third quarter. Avoro Capital Advisors LLC now owns 10,808,080 shares of the company's stock valued at $262,096,000 after purchasing an additional 5,808,080 shares during the period. Adage Capital Partners GP L.L.C. lifted its holdings in Centessa Pharmaceuticals by 35.8% during the 1st quarter. Adage Capital Partners GP L.L.C. now owns 6,954,000 shares of the company's stock worth $99,999,000 after buying an additional 1,834,973 shares in the last quarter. Federated Hermes Inc. purchased a new position in Centessa Pharmaceuticals in the 3rd quarter valued at approximately $42,429,000. Balyasny Asset Management L.P. acquired a new position in shares of Centessa Pharmaceuticals in the second quarter worth $16,052,000. Finally, Commodore Capital LP increased its position in shares of Centessa Pharmaceuticals by 39.3% during the second quarter. Commodore Capital LP now owns 3,298,289 shares of the company's stock worth $43,340,000 after acquiring an additional 930,711 shares during the period. Institutional investors and hedge funds own 82.01% of the company's stock.</p>
<div class="lb-trans"><p>几家对冲基金最近对 CNTA 的持仓进行了调整。Avoro Capital Advisors LLC 在第三季度将其在 Centessa Pharmaceuticals 的股份增加了 116.2%。Avoro Capital Advisors LLC 现在拥有 10,808,080 股该公司的股票，价值 $262,096,000，此前在此期间又购买了 5,808,080 股。Adage Capital Partners GP L.L.C. 在第一季度将其在 Centessa Pharmaceuticals 的持股增加了 35.8%。Adage Capital Partners GP L.L.C. 现在拥有 6,954,000 股该公司的股票，价值 $99,999,000，此前在上个季度又购买了 1,834,973 股。Federated Hermes Inc. 在第三季度购买了 Centessa Pharmaceuticals 的新头寸，价值约为 $42,429,000。Balyasny Asset Management L.P. 在第二季度获得了 Centessa Pharmaceuticals 的新头寸，价值 $16,052,000。最后，Commodore Capital LP 在第二季度将其在 Centessa Pharmaceuticals 的持仓增加了 39.3%。Commodore Capital LP 现在拥有 3,298,289 股该公司的股票，价值 $43,340,000，此前在此期间又购买了 930,711 股。机构投资者和对冲基金持有公司股票的比例为 82.01%。</p>
</div><h2>Centessa Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Centessa Pharmaceuticals 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.</p>
<div class="lb-trans"><p>Centessa Pharmaceuticals plc 是一家临床阶段的制药公司，致力于为患者发现、开发和提供药物。其产品管线包括 SerpinPC，一种用于治疗 A 型和 B 型血友病的活化蛋白 C 抑制剂；以及 ORX750，一种用于治疗嗜睡症和其他睡眠障碍的口服 OX2R 激动剂。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另请参阅</h2>
</div><ul>
<li>Five stocks we like better than Centessa Pharmaceuticals</li>
<li>Insider Selling Explained: Can it Inform Your Investing Choices?</li>
<li>4 Cold-Weather Stocks to Buy as Winter Spending Heats Up</li>
<li>A Deeper Look at Bid-Ask Spreads</li>
<li>Disney Stock Drops—Will Earnings Pave Way for a YouTube TV Truce?</li>
<li>Dividend Screener: How to Evaluate Dividend Stocks Before Buying</li>
<li>Meta’s Pain May Be Your Gain: Is This a Rare Buying Window?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Centessa Pharmaceuticals</li>
<li>内部人士出售解释：它能否影响你的投资选择？</li>
<li>4 只寒冷天气股票，适合冬季消费热潮</li>
<li>深入了解买卖差价</li>
<li>迪士尼股票下跌——收益能否为 YouTube TV 和解铺平道路？</li>
<li>股息筛选器：如何在购买前评估股息股票</li>
<li>Meta 的痛苦可能是你的机会：这是一个罕见的买入窗口吗？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q05UQQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=CNTA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Centessa Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Centessa Pharmaceuticals 吗？</h2>
</div><p>Before you consider Centessa Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Centessa Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Centessa Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Centessa Pharmaceuticals 并不在名单上。</p>
</div><p>While Centessa Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Centessa Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Lifesci Capital 对 CNTA 的收益发布了乐观的预测